This transcript has been edited for clarity.
Hello. I'm Dr Maurie Markman from Cancer Treatment Centers of America in Philadelphia. I want to briefly discuss a very interesting abstract presented in the gynecologic cancer session at the recently completed American Society of Clinical Oncology meeting in Chicago.
The randomized phase 3 trial called SOLO3 compared single-agent olaparib versus chemotherapy in the management of recurrent platinum-sensitive ovarian cancer in patients with a known BRCA mutation who had received two or more lines of prior chemotherapy. The study demonstrated an improvement in objective response rate of 72.2% for olaparib versus 51.4% for chemotherapy. In addition, there was a statistically significant improvement in progression-free survival in favor of the olaparib-treated patients.
This is an important study. Hopefully the US Food and Drug Administration will agree and approve the use of this particular poly(ADP)-ribose polymerase (PARP) inhibitor as second-line or later therapy in the platinum-recurrent setting. One can anticipate seeing future studies with this and other PARP inhibitors directly compared with chemotherapy, either as single agents or in combination, in patients with BRCA mutations. We have seen very impressive data for maintenance strategies; this represents a treatment strategy. It's clear that PARP inhibitors are playing—and will continue to play—a major role in the management of epithelial ovarian cancer. This is one additional study demonstrating the utility of this approach.
Medscape Oncology © 2019 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: Maurie Markman. New Data Suggest Earlier Olaparib for BRCA-Positive Ovarian Cancer - Medscape - Aug 13, 2019.